Quest Diagnostics Files 8-K on Financial Results & Other Events

Ticker: DGX · Form: 8-K · Filed: 2024-02-01T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, corporate-update, 8-K

TL;DR

**Quest Diagnostics just dropped an 8-K on its financials and other news, so keep an eye out for details.**

AI Summary

Quest Diagnostics Inc. filed an 8-K on February 1, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that the company is providing an update on its financial performance and other significant developments. For investors, this matters because it offers a timely snapshot of the company's health and any new information that could impact its future stock price, allowing them to make informed decisions.

Why It Matters

This filing provides investors with crucial, up-to-date information on Quest Diagnostics' financial performance and any other material events, which can directly influence stock valuation and investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and other events, not indicating any immediate new risks but rather providing transparency.

Analyst Insight

A smart investor would review the full content of the 8-K once available to understand the specific financial results and 'Other Events' mentioned, as this filing is a precursor to more detailed information that could impact the stock.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by Quest Diagnostics Inc.?

The primary purpose of this 8-K filing, dated February 1, 2024, is to report on 'Results of Operations and Financial Condition' and 'Other Events' as per Item Information.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 1, 2024, which is also the Date of Report.

What is the trading symbol and the exchange where Quest Diagnostics Inc.'s common stock is registered?

Quest Diagnostics Inc.'s Common Stock has the trading symbol 'DGX' and is registered on the New York Stock Exchange.

What is the state of incorporation for Quest Diagnostics Inc.?

Quest Diagnostics Inc. is incorporated in Delaware, as stated in the filing.

What is the business address and phone number of Quest Diagnostics Inc. as listed in the filing?

The business address is 500 Plaza Drive, Secaucus, NJ 07094, and the business phone number is (973) 520-2700.

From the Filing

0001022079-24-000009.txt : 20240201 0001022079-24-000009.hdr.sgml : 20240201 20240201064900 ACCESSION NUMBER: 0001022079-24-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240201 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240201 DATE AS OF CHANGE: 20240201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 24584992 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 dgx-20240201.htm 8-K dgx-20240201 0001022079 false 0001022079 2024-02-01 2024-02-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) : February 1, 2024 Quest Diagnostics Inc orporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I.R.S. Employer Identification No.) 500 Plaza Drive Secaucus, NJ 07094 (Address of principal executive offices) (Zip Code) (973) 520-2700 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition On February 1, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.      Item 8.01. Other Events On February 1, 2024, the Company announced that its Board of Directors had authorized a 5.6% increase in its quarterly dividend from $0.71 to $0.75 per share, or $3.00 per share annually, effective with the dividend payable on April 22, 2024 to shareholders of record of Quest Diagnostics Incorporated common stock on April 8, 2024. The Company has raised its dividend annually since

View on Read The Filing